{
  "validation_date": "2026-01-24",
  "total_predictions_validated": 50,
  "summary": {
    "FDA_APPROVED": 18,
    "CLINICAL_TRIAL": 4,
    "RESEARCH_SUPPORTED": 9,
    "NOVEL_HYPOTHESIS": 1,
    "FALSE_POSITIVE": 9
  },
  "metrics": {
    "precision": "77.5%",
    "false_positive_rate": "20.0%",
    "fda_validation_rate": "45.0%"
  },
  "false_positive_patterns": [
    {
      "pattern": "Drugs that CAUSE the target condition as adverse effect",
      "examples": [
        "Temsirolimus -> T2D (mTOR inhibitors cause 13-50% incidence of diabetes)",
        "Paroxetine -> hypertension (SSRIs cause hypertension, WHO signal)",
        "Mirtazapine -> hypertension (alpha-2 antagonists increase norepinephrine)",
        "Isotretinoin -> rheumatoid arthritis (causes RA-like arthritis in 16-25%)",
        "Vemurafenib -> rheumatoid arthritis (BRAF inhibitors cause arthralgia in 31-58%)",
        "Digitoxin -> T2D (cardiac glycosides inhibit Na+/K+-ATPase, worsen glucose)"
      ],
      "recommendation": "Cross-reference against FAERS adverse event database"
    },
    {
      "pattern": "Targeted therapy for cancers lacking the target",
      "examples": [
        "Trastuzumab -> melanoma (0% HER2 expression in melanoma)"
      ],
      "recommendation": "Check target expression before predicting targeted therapies"
    },
    {
      "pattern": "Wrong drug formulation for disease",
      "examples": [
        "Diflorasone (topical) -> rheumatoid arthritis (topical steroids can't treat systemic disease)"
      ],
      "recommendation": "Check drug formulation/route of administration"
    },
    {
      "pattern": "Chemotherapy for pediatric autoimmune",
      "examples": [
        "Gemcitabine -> juvenile idiopathic arthritis (cytotoxic drugs inappropriate when biologics available)"
      ],
      "recommendation": "Exclude cytotoxic chemotherapy for pediatric autoimmune conditions"
    }
  ],
  "key_validated_predictions": [
    {
      "drug": "Pitavastatin",
      "disease": "rheumatoid arthritis",
      "evidence": "Clinical trial: superior to methotrexate alone"
    },
    {
      "drug": "Everolimus",
      "disease": "rheumatoid arthritis",
      "evidence": "Phase II RCT: ACR20 36.1% vs 16.7% placebo (p=0.022)"
    },
    {
      "drug": "Sirolimus",
      "disease": "psoriasis",
      "evidence": "RCT: 63.7% PASI reduction with cyclosporine combo"
    },
    {
      "drug": "Lovastatin",
      "disease": "multiple myeloma",
      "evidence": "Phase I/II: 88% response with TLD regimen"
    },
    {
      "drug": "Fluvastatin",
      "disease": "hypertension",
      "evidence": "Meta-analysis: -1.42 mmHg SBP, modest but significant"
    },
    {
      "drug": "Cerulenin",
      "disease": "malaria",
      "evidence": "Preclinical: inhibits Plasmodium FAS (IC50 11-20 uM)"
    }
  ],
  "filter_rules_to_add": [
    "mTOR inhibitors (temsirolimus, everolimus, sirolimus) for metabolic diseases -> EXCLUDE",
    "SSRIs/SNRIs for hypertension -> EXCLUDE",
    "Alpha-2 antagonist antidepressants (mirtazapine) for hypertension -> EXCLUDE",
    "Retinoids (isotretinoin, tretinoin) for arthritis -> EXCLUDE",
    "BRAF inhibitors for arthritis -> EXCLUDE",
    "Cardiac glycosides for diabetes -> EXCLUDE",
    "HER2-targeted drugs for HER2-negative cancers -> EXCLUDE",
    "Topical steroids for systemic diseases -> EXCLUDE"
  ],
  "files_created": [
    "data/analysis/validation_batch_20260124.json",
    "data/analysis/prediction_validation_batch2.json",
    "data/analysis/validation_batch_20260124_session2.json",
    "data/analysis/validation_session3.json",
    "data/analysis/target_boost_validation.json"
  ]
}
